Earnings call transcripts

Earnings call transcripts with speakers and Q&A, usually within hours. Each one comes with a summary, the guidance management gave, and what analysts pressed on, free to read.

3,601 transcripts · 1,695 companiesHow to read a callBy API: the earnings call transcripts API.

Older calls

Page 96 of 301 · 3,601 calls

  • A.K.A. Brands Holding (AKA) Q2 2026 earnings call

    Management framed Q2 as evidence that operational discipline is converting channel expansion and better inventory into profitable growth, despite weakness in Australia and New Zealand.

    Aug 05, 2026Confident0.72
  • Akebia Therapeutics (AKBA) Q2 2026 earnings call

    The call shifted emphasis from quarterly execution to earlier-than-expected VOICE validation and a potentially differentiated rare-kidney pipeline.

    Aug 05, 2026Confident0.82
  • Arcutis Biotherapeutics (ARQT) Q2 2026 earnings call

    Management portrayed accelerating demand, broader access initiatives, and reinvestment as supporting sustained Zareve growth beyond 2026.

    Aug 05, 2026Confident0.90
  • Biodesix (BDSX) Q2 2026 earnings call

    Management framed Q2 as durable diagnostic acceleration with disciplined hiring, expanding margins, and continued progress toward profitability.

    Aug 05, 2026Confident0.84
  • Bumble (BMBL) Q2 2026 earnings call

    The call positioned Bumble as exiting its quality and technology reset, with product velocity and brand reinvestment now replacing margin preservation as priorities.

    Aug 05, 2026Positive0.65
  • Caris Life Sciences (CAI) Q2 2026 earnings call

    Management framed Q2 as proof that the reorganized commercial engine is gaining traction while investment accelerates for Detect and the broader pipeline.

    Aug 05, 2026Confident0.82
  • Carlsmed (CARL) Q2 2026 earnings call

    Management framed growth as increasingly durable, with reimbursement and product launches positioned as larger 2027 catalysts than second-half 2026 drivers.

    Aug 05, 2026Confident0.82
  • Traeger (COOK) Q2 2026 earnings call

    Management portrayed 2026 as a controlled transition, prioritizing profitability and distribution expansion despite weaker meter demand and channel disruption.

    Aug 05, 2026Mildly positive0.35
  • Cytek Biosciences (CTKB) Q2 2026 earnings call

    Management framed Q2 as evidence of U.S. and China momentum, while emphasizing new products and recurring revenue as longer-term growth drivers.

    Aug 05, 2026Positive0.55
  • DoorDash (DASH) Q2 2026 earnings call

    Management framed growth as increasingly self-reinforcing, with improving unit economics funding continued investment across grocery, international, autonomy, and merchant software.

    Aug 05, 2026Confident0.82
  • Evolus (EOLS) Q2 2026 earnings call

    Management framed the quarter as an inflection point, with portfolio breadth, improving aesthetics demand, and disciplined investment supporting higher confidence.

    Aug 05, 2026Confident0.84
  • Expedia Group (EXPE) Q2 2026 earnings call

    Management framed Q2 as evidence that product gains, disciplined marketing and B2B momentum are translating into growth, while warning of tougher comparisons and near-term margin pressure.

    Aug 05, 2026Confident0.72

Companies covered

1,695 companies

160 more under A